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Purpose of Review 
We provide an overview of recent publications that extend clinically relevant knowledge 
relating to metformin’s effects on lipids and atherosclerotic vascular disease and/or provide 
insights into the drug’s mechanisms of action on the heart and vasculature.  
Recent findings 
We focus on original research in humans or in human tissues.  Several recently completed 
randomised clinical trials have reported effects of metformin on surrogate measures of 
atherosclerotic vascular disease, including carotid intima media thickness, vascular reactivity 
and calcification in people with Type 1 (T1D) and Type 2 (T2D) diabetes as well as non-
diabetic dysglycemia.  In addition, observational studies have provided novel insights into the 
mechanisms of metformin’s effects on carotid plaque, monocytes/macrophages, vascular 
smooth muscle and endothelial cells, including via 5’-adenosine monophosphate-activated 
protein kinase (AMPK) activation.  
Summary 
Recent trials based on surrogate outcome measures have provided further data suggesting 
protective effects of metformin against vascular disease in youth and adults with Type 1 
diabetes, as well as in adults with pre-diabetes and Type 2 diabetes.  In parallel, human tissue 
and cell studies have provided new insights into pleiotropic effects of metformin and suggest 
novel drug targets. As metformin is an inexpensive agent with an established safety profile, 
larger scale clinical trials based on hard clinical outcomes [cardiovascular disease (CVD) 
events] are now indicated.  
 
Keywords 
Metformin, Lipoproteins, Atherosclerosis, Vascular Function, Diabetes Mellitus 
 
3 
 
Key points: 
Metformin has been in clinical use for glucose control in T2D for over 60 years and has 
proven effects in reducing progression from pre-diabetes to T2D and in reducing rates of 
cardiovascular disease (CVD) events and death in T2D. These actions occur in part via 
glucose lowering, and in part via other "pleiotropic" effects.  
Other than the recent REMOVAL trial, very few clinical trials have studied the effect of 
metformin on vascular complications in T1D. 
Understanding of the mechanisms of metformin’s apparently protective effects on vascular 
cells is gradually accumulating, including effects related to AMPK, scavenger receptors, 
hTERT, DNA methylation and mitochondrial biogenesis.  
Surrogate end-point trials in high CVD risk adults (carotid intima media thickness) and in 
young people (vascular reactivity) with T1D support beneficial actions of metformin on the 
vasculature.  These results highlight the need for CVD outcome trials.  
In clinical studies of pre-diabetes and T2D, metformin has favourable effects including 
reduction of vascular calcification and novel vascular risk factors. 
 
 
 
 
 
 
4 
 
Introduction 
The biguanide metformin has been used for over 60 years as the first-line oral agent for 
glucose lowering in Type 2 diabetes (T2D) [1]. Metformin also retards progression from pre-
diabetes to T2D [2] and, as shown by the UK Prospective Diabetes Study (UKPDS), reduces 
cardiovascular disease (CVD) events and mortality in T2D [3,4].   Metformin lowers glucose 
by reducing glucose absorption from the gut and inhibiting hepatic glucose output [1].  In 
pre-diabetes and T2D metformin improves beta cell function and improves clustered 
metabolic risk factors [5].  Unlike most glucose control agents metformin induces visceral fat 
loss and reduces waist circumference [6].   Metformin is quite frequently used off-label as an 
insulin-sparing glucose control agent in overweight/obese people with Type 1 diabetes 
(T1D), though this is based on relatively small short duration studies [7]. 
 Metformin’s beneficial effects have been postulated to extend beyond glycemia, to effects on 
multiple other pathways mediating complications, including lipoproteins, inflammation, 
thrombosis and oxidative stress ("pleiotropic" effects) [1,8].  Metformin is low cost with an 
excellent safety profile, other than appreciable rates of gastrointestinal upset [1], which can 
be reduced with meal-time dosing and extended release preparations [8].  Metformin reduces 
Vitamin B12 absorption, which may increase homocysteine levels but is currently thought to 
have only marginal clinical relevance in  terms of neuropathy risk [9].  Lactic acidosis is a 
rare side-effect, the risk of which is increased with renal impairment [1], hence 
recommendations to avoid use in late-stage CKD [10, 11]. Pleiotropic effects and 
mechanisms of action of metformin are still being identified: recent studies are reviewed 
herein. 
Metformin is therefore a candidate for more widespread clinical use, particularly in an aging 
and obese population.  Recent publications report surrogate measures of vascular disease in 
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randomized controlled trials (RCTs) of metformin in T1D, pre-diabetes and T2D.  Other 
papers report effects on novel vascular risk factors and provide insights into metformin’s 
cellular actions.   
Metformin’s cardiometabolic effects in Type 1 diabetes  
Interest in metformin as an insulin adjunct in T1D has arisen because of the benefits and 
challenges of optimizing glycemia [12] and an increased rate of adiposity, which is associated 
with increased vascular complications [13,14].  In the 2000s a series of small short-term trials 
of metformin reported modest benefits for weight, insulin dose and LDL-cholesterol (LDL-
C); meta-analyses confirmed a significant reduction in insulin dose requirement (6.6 IU/day, 
p < 0.001) with metformin, and weight reduction in some trials [7,15].  Although there was 
no consistent evidence for HbA1c reduction, the UK National Institute for Health and Care 
Excellence  (NICE) and the American Diabetes Association (ADA) recommended metformin 
for overweight/obese T1D patients for improving glycemia while limiting insulin dose 
[15,16].  Subsequently in 140 overweight/obese adolescents with high HbA1c and insulin 
doses, 26 weeks of metformin treatment induced only a small (transient) reduction in HbA1c, 
and small reductions in BMI and insulin dose, with no change in lipids. No vascular 
measurements were made in this trial. [17]   
The REversing with MetfOrmin Vascular Adverse Lesions (REMOVAL) Trial addressed 
cardiometabolic health in T1D adults at high CVD risk [18-21]. REMOVAL is the largest 
and longest trial of metformin in T1D and the first to evaluate a CVD end-point, albeit a 
surrogate measure of carotid intima media thickness (cIMT).  REMOVAL also included a 
vascular reactivity substudy.  In this multicentre international RCT 428 adults aged ≥40 
years, with ≥5-years T1D and ≥3 of 10 CVD risk factors were randomized to placebo or 
metformin (1000 mg b.d. or lower if not tolerated) with insulin titrated towards HbA1c 7% 
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(53 mmol/mol) [18,19].  Participants were followed for a mean of three years with annual 
assessments of cIMT, vascular reactivity, renal and retinal status, CVD risk factors and side-
effects [18,19].  cIMT was chosen as a surrogate CVD measure for several reasons: the need 
for a shorter smaller clinical trial than that required by clinical vascular end-point studies; 
because cIMT predicts CVD in the general population [22]; and because in the (T1D) 
Diabetes Control and Complications Trial (DCCT) intensive management reduced cIMT 
[23], which over 30 years follow-up was associated with better CVD outcomes [12].  cIMT is 
increased even in children with T1D [24].   
REMOVAL participants had a mean age of 55 years, with 33 years T1D, blood pressure 
130/72 mmHg, LDL-C 2.1 mmol/l.  BMI indicated overweight/obesity in 71% whilst 82% 
were on statins, 73% were on anti-hypertension agents, and 39% were on antiplatelet agents 
[19].   
Relative to placebo the primary end-point of mean far wall cIMT (as per the Mannheim 
consensus, which excludes IMT measures >1.5 mm and plaque) was not significantly 
reduced. However, maximal cIMT (tertiary end-point), which includes plaque, was reduced 
by metformin (-0.01mm, p=0.0093) [19]. Vascular reactivity and (retinal photo-based) 
retinopathy progression did not differ between treatment arms. Renal function, assessed by 
eGFR increased (mean 4 ml/min/1.73m
2
) soon after metformin commencement then declined 
in parallel with the placebo group, resulting in apparently better renal function with 
metformin [19].  Further renal measures are being assessed, but interestingly a similar trend 
(of borderline statistical significance) was recently observed in a one year pilot feasibility 
study for a planned CV outcome trial with metformin in prediabetes (the Glucose Lowering 
In Non-diabetic hyperglycaemia Trial (GLINT) [25].  Metformin was associated with a 
transient 0.24% (2.6 mmol/mol) HbA1c reduction, with no difference in severe hypoglycemia 
or DKA rates [19].  Metformin allocation was associated with sustained small weight loss 
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(1.17 kg), LDL-C reduction (0.13 mmol/l) and a 2 U/day reduction in insulin dose.   Relative 
to placebo, about double the number of participants allocated metformin discontinued 
treatment; mean metformin dosage was 1.4 g/day, with high rates of gastrointestinal upset, 
and a higher rate (12% vs. 5%) of Vitamin B12 deficiency. There were only three CVD (of 
seven) deaths, two with metformin and one with placebo [19].  Overall, the results were in 
keeping with non-glucose mediated atheroprotective effects of metformin in T1D and 
supported the need for CVD event end-point studies.   
Metformin improves vascular function in youth with Type 1 diabetes.   
Vascular reactivity, such as ultrasound measured brachial artery dilatation (flow mediated 
dilatation (FMD) and/or by GTN), is associated with and predictive of CVD [26] and 
coronary artery calcification (CAC) [27], and is abnormal in T2D [28] and T1D [29]. 
Changes in FMD- and GTN-induced reactivity can be discordant, as FMD is dependent on 
NO released from endothelium while GTN, a NO donor, directly affects vascular smooth 
muscle and is therefore endothelium independent [30].    
 In a single paediatric centre experienced in FMD- and GTN-mediated vascular reactivity 
(CVs≤4%) a one year double-blind placebo-controlled trial of metformin (with weight 
appropriate doses up to 1000 mg b.d.) was conducted in 90 youth aged 8-18 years, ≥6-months 
T1D and above average weight (BMI >50
th
 percentile) [31].  Youth on or with a 
contraindication to metformin, or on statins, blood pressure drugs or multivitamins, or with 
recent severe hypoglycemia, DKA, or serious comorbidities were excluded. Vascular 
reactivity was measured at baseline, 3-, 6- and 12-months.  Whilst the primary end-point, 
FMD, was unchanged, metformin improved GTN-induced reactivity (3.3%, p=0.03) 
independent of improved HbA1c.  As expected, given the short duration, there were no 
changes in carotid or aortic IMT.  Metformin reduced HbA1c (1%, p=0.001), with greater 
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benefit at 3-months, when adherence was greater, and lowered insulin doses, and leptin over 
12-months. BMI, body composition, blood pressure, renal function, lipids, homocysteine, 
CRP, and adiponectin did not change significantly [31].  Ten subjects discontinued treatment 
(six on metformin) and mean tablet adherence was 75%, similar in both study arms.  Lactate 
levels did not change and there were no episodes of lactic acidosis, severe hypoglycemia or 
DKA. Metformin slightly  reduced Vitamin B12, though levels were still within normal 
range, and homocysteine did not rise [31].  
FMD results were negative in this paediatric cohort [31], as was the Reactive Hyperemia 
Index in the REMOVAL Study [19], but GTN-induced hyperemia was improved by 
metformin in T1D youth [31].  Important study differences include the methodology of 
assessment (GTN was not used in REMOVAL), and subject demographics, including age, 
T1D duration, complications and medications.  The positive (albeit non-primary) end-points 
in both studies provide clinicians with additional evidence of a potential vascular benefit of 
adjunct metformin therapy in T1D.  These data are corroborated by recent studies in the STZ-
diabetic mouse model in which metformin improved endothelial function and increased bone 
marrow derived endothelial progenitor cells (EPCs) [32], with clinical confirmation of the 
latter in the T1D MERIT study [33].  
Surrogate endpoint data from recent trials therefore support the need for clinical CVD end-
point trials with metformin in T1D.  The likelihood of such trials being funded either by 
research charities, governmental agencies or pharmaceutical companies currently seems low 
given that thousands of patients would need to be randomised over several years of follow-up 
and metformin has long been available in generic form.  
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Metformin vascular effects in pre-diabetes and Type 2 diabetes  
As mentioned above, a beneficial effect of metformin on CVD outcomes in people with T2D 
is often considered quite established, on the basis of the UKPDS [3,4] in 1998 and also (in 
insulin-treated patients) the HOME study (n=390) in 2009 in which the hazard ratio for 
reduction of CVD events over 4.3 years of follow-up was 0.61 (95% CI, 0.40-0.94, p=0.02) 
[34].  However, when all available data are subjected to meta-analysis some uncertainty 
remains [35].  One recent small but interesting clinical trial (based on surrogate measures) 
aimed to examine some of the relevant mechanisms and gain insights into "first-line" use of 
metformin as opposed to other agents in T2D.  
The Sapporo Athero-Incretin Study 3 in T2D patients on 500-750 mg/day metformin 
evaluated if doubling the dose of metformin or adding a DPP-4 inhibitor (vildagliptin), which 
has glucose lowering, anti-inflammatory and anti-atherosclerotic actions, improved brachial 
artery FMD (primary end-point) and novel vascular risk factors [36]. The study randomised 
97 patients with T2D (mean (SD) age 58.7(11.0) years, HbA1c 7.5 (0.3) %) to vildagliptin or 
higher dose metformin for 12-weeks. There was no significant FMD change in either group. 
Metformin/vildagliptin lowered HbA1c more (-0.80 (0.38)% vs. -0.40 (0.47)%; p<0.01) than 
high dose metformin. Reductions in ApoB/A1 were significant, but similar with both 
treatments [36].  Thus, whilst combination therapy was effective in terms of glycaemia, no 
differences in effects on vascular or lipid parameters could be discerned between the two 
strategies.  
In people without diabetes, the effect of metformin on CVD is much less certain.  For 
example, in the double-blind, placebo-controlled Carotid Atherosclerosis MEtformin for 
Insulin ResistAnce Study (CAMERA) trial in people with established CVD but without 
diabetes, metformin treatment for 18 months had no effect on progression of mean cIMT (the 
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primary endpoint) or on total cholesterol, HDL-cholesterol, non-HDL-cholesterol, or 
triglycerides [37]. However, data suggesting an effect of metformin on vascular calcification 
in dysglycemic subjects have been reported [38, 39].   
The Diabetes Prevention Program (DPP) is the longest (1996-2001) and largest (n=3234) trial 
of lifestyle or metformin for T2D prevention in adults with pre-diabetes and is in follow-up 
(DPP/Diabetes Prevention Program Outcomes Study (DPPOS), with an emphasis on 
cardiometabolic outcomes, cancer and long-term safety. An excellent review of the 
DPP/DPPOS was published in 2017 [40]. In brief, the DPP demonstrated that relative to 
placebo, over a mean 3.2 years follow-up, metformin 850 mg b.d. reduced progression to 
T2D by 31%, with greater benefit in the obese and in women with prior gestational diabetes.  
Intensive lifestyle reduced progression by 58%.  Ten and 15-year follow-up (DPPOS) 
demonstrated 18% T2D reduction with metformin. HbA1c, fasting glucose, hepatic glucose 
output, beta cell function and insulin/proinsulin improved significantly.  Most benefit (64%) 
was explained by weight reduction and decreased central adiposity (DPP) [38,40].  
Metformin did not improve lipid (triglycerides, LDL-C or HDL-C) levels or blood pressure, 
but improved CRP and tissue plasminogen activator (tPA) levels [40].  To date no reductions 
in microvascular complications have been reported and CVD events are still being monitored 
[40].   
In a DPP/DPPOS substudy (n=2029) a mean 14-years post-randomization, CAC was 
quantified in men [mean age 67 years] and women (mean age 63 years] [38].  T2D had 
developed in 54%, 51% and 59% of the metformin, lifestyle and placebo groups respectively.  
Relative to placebo, metformin (for 9.6 (9.4) years) was associated with lower presence of 
CAC (i.e. CAC score above zero)  (75 vs. 84%, p=0.02) and severity (39.5 vs. 66.9 Agatson 
units, p=0.04) in men only.  This metformin benefit was independent of age, BMI, 
progression to diabetes or statin use [38]. Long-term safety and tolerability was good, with 
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(predominantly gastrointestinal) side-effects in 9.8% of metformin-allocated patients (vs. 
1.1% placebo) and lower Vitamin B12, but no lactic acidosis with >15,000 patient years of 
metformin [40]. Rates of clinical CVD events from the ongoing follow-up study are awaited.  
Calcium scores in peripheral vascular disease.  In a cross-sectional study of 198 people with 
T2D those on metformin (81%) had a 41% lower prevalence of below knee vascular 
calcification and lower serum IL-6 levels than non-metformin users (independent of age, 
diabetes duration, gender, smoking, lipids, HbA1c, eGFR, prior CVD, retinopathy, 
neuropathy, insulin and IL-6 levels) [39].  This observation is supported by lower rates of 
lower limb amputation rates in T2D patients treated with metformin vs. sulfonylurea or 
insulin monotherapy [41].   
These two studies suggest that metformin may protect against vascular calcification in 
dysglycemia.  Potential mechanisms include anti-inflammatory, antioxidant and specific anti-
calcification effects which may relate to AMPK activation [1,8,42,43].   
 We believe that there is sufficient evidence to support the commissioning of a cardiovascular 
endpoint trial of metformin in people without diabetes and have recently contributed to a 
feasibility trial (GLINT) [25].  If commissioned, this will provide more definitive evidence of 
metformin's effects on CVD and the results will have implications for people with and 
without diabetes (whether T1D or T2D).     
Metformin effects on novel vascular risk factors 
Glucagon-like peptide (GLP)-1.  Mechanism(s) of metformin delaying glucose uptake from 
the gut have not been fully elucidated.  GLP-1 receptor agonist trial data in T2D support 
CVD safety and in some cases efficacy against CVD, with further evidence awaited [44].  In 
a substudy (n=173) of the above-mentioned CAMERA trial of patients without diabetes 
12 
 
metformin sustainably (at least 18 months) increased (≈23%) total GLP-1 levels, independent 
of changes in glycemia or weight,] but did not reduce cIMT [45]. This is the largest and 
longest metformin study evaluating GLP-1. In a DIRECT consortium (n=775 T2D subjects) 
study metformin use was associated with 14.1% higher total GLP-1 and 39.1% higher fasting 
active GLP-1, independent of HbA1c, weight or gender, but post-prandial levels did not 
differ from other therapies [46].  These exploratory studies support a role for the incretin axis 
as a component of the mechanism of metformin’s cardiometabolic effects.  
Neutrophil Gelatinase Associated Lipocalin (NGAL). In an observational study, circulating 
neutrophil-derived acute phase protein was measured in 67 T2D and 69 non-diabetic subjects 
and also in their carotid endarterectomy samples (mRNA expression) [47].  Relative to non-
diabetic control samples, circulating NGAL levels were >50% higher in T2D, and 
significantly higher in those with carotid artery stenosis (CAS), whether symptomatic or 
asymptomatic. NGAL mRNA was present in 95% of T2D endarterectomy tissues vs. 5% 
from non-diabetic subjects (p<0.0001). Those (n=17) who were prescribed metformin had 
lower NGAL (60.7 vs. 121.7 ng/ml, p<0.0001) and carotid tissues from these individuals had 
less leukocyte infiltration and more complex and vulnerable plaques [47].      
Metformin effects in vascular cells  
Uptake of lipids, including Oxidized LDL (Ox-LDL) by macrophages and their subsequent 
apoptosis are key steps in atherosclerosis; there is evidence that metformin can inhibit both of 
these.  In human THP-1 cells, a monocyte-like cell line, it was demonstrated that metformin 
can attenuate: (i) Ox-LDL uptake by reducing scavenger receptor (SRA and CD36) 
expression by suppression of β-catenin, activating protein (AP)-1 and PPAR-γ; (ii) Ox-LDL 
induced endoplasmic reticulum stress and reactive oxygen species generation and (iii) Ox-
LDL induced mitochondrial membrane depolarisation and cyto-C release [48]. In the same 
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cell line, an independent group reported that metformin-induced activation of AMPK, inhibits 
Sterol Regulatory Element-Binding Protein 2 (SREBP2)-mediated cholesterol uptake [49].   
In experiments using THP-1 cells and macrophages from T2D patients cultured in high 
glucose, metformin activated AMPK by reducing (proinflammatory) cyclophilin A 
expression, and suppressed scavenger receptors and lipid uptake, foam cell formation, 
reactive oxygen species toxicity, and inflammatory cytokine release [50]. 
Two studies evaluated the role of AMPK activation by metformin in other vascular cells.  In 
cultured human aortic smooth muscle cells metformin activated AMPK, upregulating p53 and 
IF116, inhibiting cell proliferation and migration [51].   In cultured (early passage) human 
aortic endothelial cells metformin activated AMPKα and induced telomere extending hTERT, 
delaying cell senescence [52]. Chronic metformin reduced mitochondrial biogenesis, which 
was dependent on H3K79 methylation in the SIRT3 promoter. In complementary 
experiments in ApoE-/- mice, metformin decreased vascular aging and plaque formation [52].  
Results of human studies with metformin are summarized (Table 1). 
 Conclusions   
Recent studies reveal new knowledge of an old drug’s cardiometabolic effects, supporting the 
case for cardiovascular outcome trials in individuals with T1D and non-diabetic dysglycemia.  
At the same time, molecular and cellular studies are providing insights into the mechanisms 
of metformin’s actions on the vasculature, suggesting novel biomarkers that require 
validation in independent cohorts.  These studies may guide development and targeting of 
novel agents for the treatment and prevention of cardiovascular and metabolic disease.  
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Table 1.  Effects of metformin.   
Metformin Effect Evidence 
Level 
Reference 
Glucose lowering / insulin resistance   
Inhibits glucose absorption from gut II 53 
Decreases hepatic glucose output III-3 54 
Increases peripheral glucose uptake I 55 
Increases fatty acid oxidation Basic 
science 
56 
Lowers HbA1c and glucose levels in pre-diabetes and T2D II 31 
Moderate HbA1c reduction in T1D II 17, 19 
Moderate weight loss and leptin reduction in T1D II 19, 31 
Small insulin dose reduction in T1D II 19 
Increases GLP-1 levels  II  
III 
45 
46 
Lipid related   
Small LDL-C and total cholesterol reductions  I 19,57 
 
Novel risk factors:  
  
Lowers NGAL levels in circulation and atheroma in T2D III-2 47 
Lowers CRP and WBC   II 40, 58 
Lowers tPA II 40, 59 
Reduces platelet aggregation Basic 
science 
60 
Increased circulating EPC III-2 33 
   
Clinical vascular events   
Controversy regarding reduction in CVD events (including myocardial 
infarction, heart failure, stroke and atrial fibrillation) in T2D  
I 
II 
35 
3,4 
 
Surrogate vascular outcomes  
  
Retards maximum cIMT progression in T1D  II 19 
Retards CAC in pre-diabetes and T2D II 38 
Associated with lower CAC in lower limb arteries III-2 39 
Associated with lower lower limb amputations in T2D III-2 41 
Associated with less advanced, complex and inflamed carotid 
atheroma  
III-2 47 
Reduces renal filtration loss in T1D   II 19 
Improves GTN mediated vascular dysfunction in T1D youth  II 31 
Does not improve FMD  II 19, 31 
Vascular cell biology    
Activates AMPK Basic 
Science 
49-52 
Increases vascular cell eNOS  Basic 
Science 
32 
Inhibits Ox-LDL and TG uptake by macrophages, reducing foam cell 
formation and  apoptosis  
Basic 
Science 
48 
Inhibits endothelial cell senescence Basic 
Science 
52 
Reduces mitochondrial biogenesis Basic 
Science 
52 
Side-effects   
Gastrointestinal upset: Metallic taste, nausea, vomiting, diarrhoea II 19,31,40 
Lowers Vitamin B12 levels, including in T1D  II 19 
Newly documented effects with potentially vascular effects are in italics and underlined. 
